The World Health Organization has added new curative treatments for hepatitis C to its essential medicines list, but the U.N. agency said prices needed to fall to make them accessible to patients in poorer countries.
The treatment of hepatitis C, which affects about 150 million people globally and kills around half a million each year, has been transformed by the arrival of new drugs, such as Gilead's Sovaldi.
These products can cure hepatitis C but are out of reach at Western prices to patients in poor countries, with a single Sovaldi pill costing $1,000 in the United . . .
